Stan had a specific type of AML caused by a gene mutation called IDH2, found in fewer than 15% of patients with the disease, and IDHIFA was being studied in patients like him. He met all the qualifying criteria for the trial and began treatment – one IDHIFA pill daily – in July 2017.
It was not long before he noticed a change. “I seemed to be getting better. I started to feel stronger and I was having fewer blood infusions,” he says.
Six months later, after 18 trips from his Minnesota home to Houston, Stan achieved complete remission. He was cleared for a bone marrow transplant, with his brother as the donor, in February 2018.
Since it was performed, he has had several biopsies and remains in complete remission.
“I do not believe I would be here today if it weren’t for this pill,” Stan adds. “IDHIFA was the key that opened the door to my bone marrow transplant.”
Stan and Sue are celebrating their 40th wedding anniversary this year and enjoying moments they thought might be lost because of AML. “I’m doing all the things I was before,” Stan says. “For me IDHIFA wasn’t only hope, it was an answer. I’m living life again.”